Figure 2.

A pharmacokinetic model for serum galactomannan in invasive aspergillosis, as proposed by Huurneman et al. (2016). The first part of the equation estimates production of galactomannan, taking into account the effect of antifungal therapy, whereas the second part estimates the elimination from the bloodstream. x, serum galactomannan; KGM_prod, maximal rate of galactomannan production; POP_max, maximal achievable galactomannan; D, drug concentration in the central compartment; V, volume of the central compartment; H, relationship between drug concentration and reduction in galactomannan production; EC₅₀, drug concentration at which half-maximal reduction in galactomannan production is reached; KGM_elim, maximal rate of elimination of galactomannan.